Optimizing Pyrazinamide Use: A Low-Hanging Fruit in Improving Outcomes with Tuberculous Meningitis? Narrative Review

Area of Science:

• Neurology
• Infectious Diseases
• Pharmacology

Background:

• Tuberculous meningitis (TBM) causes significant disability in over a third of patients.
• Current research prioritizes rifampicin dosage optimization for TBM treatment.
• Pyrazinamide, crucial for central nervous system penetration, is often underutilized in TBM therapy.

Purpose of the Study:

• To evaluate the potential clinical impact of extending pyrazinamide use throughout tuberculous meningitis treatment.
• To contrast this extended use with the current standard of only using it during the intensive phase.

Main Methods:

• Review of in vitro studies, clinical cohorts, and toxicity data related to pyrazinamide in TBM.
• Analysis of baseline resistance rates to pyrazinamide.
• Discussion of ongoing clinical trials investigating this therapeutic approach.

Main Results:

• Pyrazinamide demonstrates higher central nervous system penetration compared to other antitubercular drugs.
• Data from existing studies suggest potential benefits for extended pyrazinamide use in TBM.
• Toxicity profiles and resistance rates are being considered in the evaluation.

Conclusions:

• Extending pyrazinamide use throughout antitubercular therapy may enhance treatment efficacy in TBM.
• This strategy holds promise for reducing long-term disability associated with tuberculous meningitis.
• Ongoing clinical trials will provide further evidence on the optimal use of pyrazinamide in TBM.